Halozyme Therapeutics Inc (HALO) - Total Liabilities
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has total liabilities worth $1.72 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Halozyme Therapeutics Inc (HALO) asset resilience to evaluate the company's liquid asset resilience ratio.
Halozyme Therapeutics Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HALO asset base.
Halozyme Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Halozyme Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brinker International Inc
NYSE:EAT
|
USA | $2.37 Billion |
|
Universal Scientific Industrial Shanghai Co Ltd
SHG:601231
|
China | CN¥19.76 Billion |
|
Praxis Precision Medicines Inc
NASDAQ:PRAX
|
USA | $49.06 Million |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
Canada | CA$19.59 Billion |
|
Brixmor Property
NYSE:BRX
|
USA | $6.07 Billion |
|
Alchip Technologies Ltd
TW:3661
|
Taiwan | NT$16.02 Billion |
|
PB Fintech Limited
NSE:POLICYBZR
|
India | Rs13.89 Billion |
|
American Airlines Group
NASDAQ:AAL
|
USA | $68.20 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Halozyme Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HALO net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Halozyme Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual total liabilities of Halozyme Therapeutics Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.70 Billion | +3.04% |
| 2023-12-31 | $1.65 Billion | -1.33% |
| 2022-12-31 | $1.67 Billion | +84.22% |
| 2021-12-31 | $907.48 Million | +111.59% |
| 2020-12-31 | $428.88 Million | -9.54% |
| 2019-12-31 | $474.11 Million | +147.76% |
| 2018-12-31 | $191.36 Million | -38.58% |
| 2017-12-31 | $311.58 Million | +5.98% |
| 2016-12-31 | $294.00 Million | +111.83% |
| 2015-12-31 | $138.79 Million | +11.37% |
| 2014-12-31 | $124.62 Million | +2.33% |
| 2013-12-31 | $121.78 Million | +41.82% |
| 2012-12-31 | $85.87 Million | +56.54% |
| 2011-12-31 | $54.86 Million | -22.73% |
| 2010-12-31 | $70.99 Million | +1.06% |
| 2009-12-31 | $70.25 Million | +14.81% |
| 2008-12-31 | $61.18 Million | +33.90% |
| 2007-12-31 | $45.69 Million | +98.58% |
| 2006-12-31 | $23.01 Million | +898.98% |
| 2005-12-31 | $2.30 Million | +45.84% |
| 2004-12-31 | $1.58 Million | +4117.05% |
| 2003-12-31 | $37.45K | +258.95% |
| 2002-12-31 | $10.43K | +217.24% |
| 2001-12-31 | $3.29K | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more